Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059771 · ClinicalTrials.gov registry record · NA
Mobile Enhancement of Motivation in Schizophrenia
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT03059771: Completed NA study, sponsored by Indiana University.
NCT03059771 is a NA study that has completed, run by Indiana University. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03059771, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
Motivation deficits are a strong determinant of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. The primary aims of this study are to conduct a pilot study using a randomized design to 1) Test the feasibility and acceptability of a personalized mobile text message intervention, Mobile Enhancement of Motivation in Schizophrenia (MEMS) and to 2) Test the preliminary effectiveness of MEMS compared to a control condition.
Primary Outcome
The percentage of baseline goals participants completed over the eight-week period will be assessed at the follow-up assessment.
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Mobile Enhancement of Motivation (MEMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2018-01-16 |
| Phase | NA |
What the finished NCT03059771 record still lists
NCT03059771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03059771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03059771 about?
NCT03059771 is a clinical study titled "Mobile Enhancement of Motivation in Schizophrenia". Motivation deficits are a strong determinant of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. The primary aims of this study a...
What is the current status of trial NCT03059771?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2017-02-28. Estimated completion is 2018-01-16.
What interventions are being tested in trial NCT03059771?
The interventions under investigation include: Control (BEHAVIORAL), Mobile Enhancement of Motivation (MEMS) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03059771?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03059771's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI